A
11.48
2.21 (23.84%)
| Penutupan Terdahulu | 9.27 |
| Buka | 10.25 |
| Jumlah Dagangan | 4,179,563 |
| Purata Dagangan (3B) | 756,085 |
| Modal Pasaran | 423,615,072 |
| Harga / Jualan (P/S) | 15.50 |
| Harga / Buku (P/B) | 30.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 Aug 2025 - 22 Aug 2025 |
| Margin Operasi (TTM) | -1,220.88% |
| EPS Cair (TTM) | -1.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 118.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 106.83% |
| Nisbah Semasa (MRQ) | 1.41 |
| Aliran Tunai Operasi (OCF TTM) | -51.82 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.61 M |
| Pulangan Atas Aset (ROA TTM) | -32.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -103.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Adlai Nortye Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
0.9
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.88 |
|
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 14.25% |
| % Dimiliki oleh Institusi | 0.18% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Eversource Wealth Advisors, Llc | 30 Sep 2025 | 719 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Dec 2025 | Pengumuman | Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China |
| 21 Nov 2025 | Pengumuman | Adlai Nortye to Participate in Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |